# Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder

> **NCT00084942** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00084942
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2004-05
- **Final completion:** 2006-11
- **Target enrollment:** — (—)
- **Last updated:** 2012-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084942, "Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00084942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*